Brief: HBM Holdings Gives Further Business Update Of Collaboration On Antibody-Drug Conjugate
14/07/2023 02:32
July 14 (Reuters) - Hbm Holdings Ltd 2142.HK :
* FURTHER BUSINESS UPDATE OF COLLABORATION ON ANTIBODY-DRUG
CONJUGATE
* BEIGENE TO ACQUIRE EXCLUSIVE OPTION FOR A GLOBAL CLINICAL
AND
COMMERCIAL LICENSE TO ADC PROGRAM FOR PATIENTS WITH SELECT SOLID
TUMORS
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study